Scroll for more
home Mar 21, 2017

Ken Mulvany talks to CNBC at Goldman Sachs’ Disruptive Technology Symposium

Listen to our founder Ken Mulvany discussing BenevolentAI's work on artificial intelligence applied to drug discovery.